Key Focus Areas for BridgeBio Pharma Investors

By Ken Smith • Thursday, April 11 15:13 • Permanent Link

With gains of 4.7%, BridgeBio Pharma was one of the winners on Wall Street today. Its shares are now trading at $28.61 and have logged a 1.0% daily outperformance of the S&P 500. Don't join the feeding frenzy before checking some basic facts about this stock:

BridgeBio Pharma has moved 74.5% over the last year, and the S&P 500 logged a change of 24.5%
BBIO has an average analyst rating of buy and is -41.6% away from its mean target price of $49.0 per share
Its trailing earnings per share (EPS) is $-3.95
BridgeBio Pharma has a trailing 12 month Price to Earnings (P/E) ratio of -7.2 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-3.03 and its forward P/E ratio is -9.4
BridgeBio Pharma is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
The company has a free cash flow of $-249069120, which refers to the total sum of all its inflows and outflows of cash over the last quarter
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.